泊洛妥珠单抗维多汀联合奥妥珠单抗和来那度胺治疗复发或难治性滤泡性淋巴瘤:一项多中心、单臂、1b/2期研究的队列
这项多中心单臂1b/2期研究在18个中心纳入56例复发或难治性滤泡性淋巴瘤患者,评估泊洛妥珠单抗维多汀联合奥妥珠单抗和来那度胺(Pola-G-Len)方案。推荐2期剂量为泊洛妥珠单抗维多汀1.4 mg/kg联合来那度胺20 mg。中位随访26.7个月,客观缓解率76%(90% CI 64-86),完全缓解率63%(90% CI 50-75)。
要点
- 推荐2期剂量为泊洛妥珠单抗维多汀1.4 mg/kg联合来那度胺20 mg。
- 客观缓解率76%(90% CI 64-86),完全缓解率63%(90% CI 50-75)。
- 最常见3-4级不良事件为中性粒细胞减少(31/56,55%)和血小板减少(14/56,25%)。
核心结论
- Pola-G-Len在既往重度治疗且难治的滤泡性淋巴瘤患者中显示出高完全缓解率,但未达到预设的活性阈值。
- 作者认为该结果与现有疗法相比具有优势,并支持在更大患者群体中进一步研究Pola-G-Len。
研究设计与样本
- 多中心、单臂1b/2期研究,在西班牙、英国和美国的18个癌症中心开展。
- 纳入年龄≥18岁、CD20阳性复发或难治性滤泡性淋巴瘤(排除3b级)、ECOG体能状态≤2且既往接受过含抗CD20化疗的患者。
- 剂量递增阶段设6个队列,给予6个28天周期诱导治疗:奥妥珠单抗1000 mg静脉注射(所有队列),泊洛妥珠单抗维多汀和来那度胺口服剂量分别为队列1(1.4 mg/kg+10 mg)、队列2(1.8 mg/kg+10 mg)、队列3(1.4 mg/kg+15 mg)、队列4(1.8 mg/kg+15 mg)、队列5(1.4 mg/kg+20 mg)、队列6(1.8 mg/kg+20 mg)。
- 泊洛妥珠单抗维多汀于第1天给药,来那度胺于第1-21天给药,奥妥珠单抗于第1周期第1、8、15天及第2-6周期第1天给药。
- 2期剂量扩展阶段给予6周期Pola-G-Len诱导治疗,剂量为剂量递增阶段确定的推荐2期剂量;诱导结束时有缓解或疾病稳定的患者进入维持治疗:奥妥珠单抗1000 mg每两个28天周期第1天给药共12次、持续24个月,来那度胺10 mg第1-21天给药共12周期、持续12个月。
主要发现
- 2016年3月24日至2018年8月23日共入组56例患者(33例[59%]男性,23例[41%]女性;49例[88%]非西班牙裔或拉丁裔)。
- 剂量递增阶段队列2的4例患者中2例报告剂量限制性毒性(1例4级淀粉酶和脂肪酶升高,1例4级中性粒细胞减少和3级血小板减少),队列3和5未观察到剂量限制性毒性;推荐2期剂量为泊洛妥珠单抗维多汀1.4 mg/kg联合来那度胺20 mg。
- 46例(82%)患者纳入活性可评估人群;中位随访26.7个月(IQR 22.2-31.3)时,客观缓解率76%(90% CI 64-86),完全缓解率63%(90% CI 50-75)。
- 中位随访27.0个月(IQR 18.7-34.0)时,最常见的3-4级不良事件为中性粒细胞减少(31/56,55%)和血小板减少(14/56,25%)。
- 35例(63%)患者报告61起严重不良事件,最常见为发热性中性粒细胞减少(5例[9%];另有1例发热性中性粒细胞减少但研究者认为不属严重)、肺炎(4例[7%])和发热(4例[7%]);1例致命不良事件(5级感染性休克)发生于因疾病进展停止研究治疗并开始新抗淋巴瘤酪氨酸激酶抑制剂治疗的患者,研究者认为与研究治疗无关。
关键数值与推荐
- 推荐2期剂量:泊洛妥珠单抗维多汀1.4 mg/kg联合来那度胺20 mg。
- 客观缓解率76%(90% CI 64-86),完全缓解率63%(90% CI 50-75)。
- 3-4级中性粒细胞减少31/56(55%),3-4级血小板减少14/56(25%)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为Pola-G-Len在重度治疗且难治的滤泡性淋巴瘤患者中显示出高完全缓解率,并支持在更大患者群体中进一步研究。
局限性
- 原文在解释中写明Pola-G-Len未达到预设的活性阈值。
- 作者在解释中提出需要在更大患者群体中进一步研究Pola-G-Len。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obinutuzumab with polatuzumab vedotin or lenalidomide showed tolerability and activity in phase 1b/2 trials that recruited patients with relapsed or refractory follicular lymphoma. We aimed to examine whether the novel polatuzumab vedotin-obinutuzumab-lenalidomide (Pola-G-Len) combination might enhance antitumour response in patients with relapsed or refractory follicular lymphoma. METHODS: This multicentre, single-arm phase 1b/2 study tested Pola-G-Len in patients with relapsed or refractory follicular lymphoma, and polatuzumab vedotin in combination with rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Here we report the results from the cohort of patients with follicular lymphoma. The trial was done in 18 cancer centres across three countries (Spain, UK, and USA). Patients (≥18 years old) with CD20-positive relapsed or refractory follicular lymphoma (excluding grade 3b) and Eastern Cooperative Oncology Group performance status of 2 or less who had previously received anti-CD20-containing chemotherapy were eligible for inclusion. During the dose-escalation phase, patients received six 28-day cycles of induction treatment with intravenous obinutuzumab 1000 mg (all cohorts), and intravenous polatuzumab vedotin and oral lenalidomide (Celgene, Summit, NJ, USA) in the following doses: 1·4 mg/kg polatuzumab vedotin and 10 mg lenalidomide (cohort 1); 1·8 mg/kg polatuzumab vedotin and 10 mg lenalidomide (cohort 2); 1·4 mg/kg polatuzumab vedotin and 15 mg lenalidomide (cohort 3); 1·8 mg/kg polatuzumab vedotin and 15 mg lenalidomide (cohort 4); 1·4 mg/kg polatuzumab vedotin and 20 mg lenalidomide (cohort 5); and 1·8 mg/kg polatuzumab vedotin and 20 mg lenalidomide (cohort 6). Polatuzumab vedotin was administered on day 1, lenalidomide on days 1-21, and obinutuzumab on days 1, 8, and 15 of cycle one and day 1 of cycles two to six of each 28-day cycle. During phase 2 (dose expansion phase), patients received six cycles of induction with Pola-G-Len at the recommended phase 2 dose established during dose-escalation. Patients who had a response or stable disease at the end of induction were eligible to enter the maintenance phase, in which they received obinutuzumab for 24 months at 1000 mg on day 1 of every other 28-day cycle for a total of 12 doses, and lenalidomide for 12 months at 10 mg on days 1-21 of each 28-day cycle for a maximum of 12 cycles. The primary activity endpoint was complete response at the end of induction. Adverse events were monitored throughout the study. The primary safety objective was to determine the maximum tolerated dose of Pola-G-Len. Analyses were in the safety population, which included all patients that received at least one dose of any of the component drugs (ie, all patients who entered the induction phases in both the escalation and expansion phases), and activity-evaluable population, which included all patients who received at least one dose of any of the component drugs at the recommended phase 2 dose (ie, all patients who received the recommended phase 2 dose in the dose escalation investigation and all patients who entered induction in the dose expansion investigation). This ongoing trial is registered at ClinicalTrials.gov, NCT02600897. FINDINGS: Between March 24, 2016, and August 23, 2018, 56 patients (33 [59%] men and 23 [41%] women; 49 [88%] non-Hispanic or Latino) were enrolled. Two of four patients in cohort 2 reported dose-limiting toxicity events during dose escalation (one patient had grade 4 amylase and lipase elevation and one patient had grade 4 neutropenia and grade 3 thrombocytopenia), and there were no dose-limiting toxicities observed in cohorts 3 or 5; therefore, the recommended phase 2 dose for the dose-expansion was 1·4 mg/kg polatuzumab vedotin plus 20 mg lenalidomide. 46 (82%) patients were included in the activity-evaluable population. After a median follow up of 26·7 months (IQR 22·2-31·3) the objective response rate was 76% (90% CI 64-86) and complete response rate was 63% (90 CI 50-75). After a median follow-up of 27·0 months (IQR 18·7-34·0), the most common grade 3-4 adverse events were neutropenia (31 [55%] of 56 patients) and thrombocytopenia (14 [25%] patients). 61 serious adverse events were reported in 35 (63%) patients; the most common of which were febrile neutropenia (five [9%] patients; a sixth patient had febrile neutropenia, but this was not considered serious by the investigator), pneumonia (four [7%] patients), and pyrexia (four [7%] patients). One fatal adverse event (grade 5 septic shock) occurred in a patient who had discontinued study treatment due to disease progression and had initiated a new anti-lymphoma tyrosine kinase inhibitor treatment. This was not considered related to study treatment by the investigator. INTERPRETATION: Pola-G-Len showed high complete response rates, although it did not reached the prespecified threshold for activity, in patients who were heavily pretreated with refractory follicular lymphoma. Our findings compare favourably with available therapies and support future investigation of Pola-G-Len in a larger patient population. FUNDING: Genentech/F Hoffmann-La Roche.
引用
- Diefenbach C, Kahl BS, McMillan A, et al. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Lancet Haematol. 2021. PMID: 34826412. doi:10.1016/S2352-3026(21)00311-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。